Thrombolysis in Myocardial − Outcomes by Optimizing Platelet Inhibition With Prasugrel Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Print
暂无分享,去创建一个
E. Antman | E. Braunwald | C. McCabe | S. Goodman | F. Verheugt | S. Wiviott | R. Corbalán | S. Meisel | Drew A. Purdy | A. Sabina | Dalby | C. Mccabe
[1] D. Hanley,et al. Response to the letter regarding the article “Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment of Diabetes (PLUTO-Diabetes) trial” , 2008 .
[2] A. French. Glucose-Insulin-Potassium Therapy in Patients with ST-Segment Elevation Myocardial Infarction , 2008 .
[3] M. Keltai,et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial , 2008, The Lancet.
[4] E. Antman,et al. Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.
[5] L. Wallentin,et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. , 2007, Cardiovascular drug reviews.
[6] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[7] B. Sobel. Optimizing cardiovascular outcomes in diabetes mellitus. , 2007, The American journal of medicine.
[8] Christopher P Cannon,et al. Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.
[9] D. Angiolillo. Antiplatelet therapy in type 2 diabetes mellitus , 2007, Current opinion in endocrinology, diabetes, and obesity.
[10] Michael J Pencina,et al. Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study , 2007, Circulation.
[11] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[12] D. Angiolillo,et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.
[13] M. O’Donoghue,et al. Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? , 2006, Circulation.
[14] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[15] C. Macaya,et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. , 2006, Journal of the American College of Cardiology.
[16] P. Gurbel,et al. Clopidogrel resistance: implications for coronary stenting. , 2006, Current pharmaceutical design.
[17] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.
[18] J. Akkerman,et al. Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[19] C. Macaya,et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.
[20] J Herlitz,et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.
[21] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[22] J. Akkerman,et al. IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi* , 2004, Journal of Biological Chemistry.
[23] Deepak L. Bhatt,et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. , 2002, The American journal of cardiology.
[24] M. Sabatine,et al. Will diabetes save the platelet blockers? , 2001, Circulation.
[25] Deepak L. Bhatt,et al. Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes , 2001, Circulation.
[26] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[27] S. Yusuf,et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.
[28] Deepak L. Bhatt,et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. , 1999, Circulation.
[29] E. Mahmud,et al. Will blocking the platelet save the diabetic? , 1999, Circulation.
[30] B Jilma,et al. Putative role of adhesion molecules in metabolic disorders. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[31] P. Fasching,et al. Elevated Circulating P-Selectin in Insulin Dependent Diabetes Mellitus , 1996, Thrombosis and Haemostasis.
[32] M. Laimins,et al. Increased platelet aggregation in early diabetus mellitus. , 1975, Annals of internal medicine.
[33] B. Gersh. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .
[34] K. Winters,et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.
[35] Joseph P Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.
[36] W. Frishman. Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATEECLA Randomized Controlled Trial , 2006 .
[37] P. Halushka,et al. Altered platelet function in diabetes mellitus. , 1976, Diabetes.